The Korea Biotechnology Industry Organization announced on the 8th that it will participate in the '2022 Bio International Convention (2022 Bio USA),' to be held at the San Diego Convention Center from the 13th to the 16th (local time), through KOTRA's overseas exhibition support program.
Bio USA is a bio exhibition with over 8,000 companies from 65 countries worldwide. Due to the impact of the COVID-19 pandemic, it was held online in 2020–2021, and this year it returns to in-person for the first time in three years. The Korea Biotechnology Industry Organization and KOTRA have continuously promoted the Korean bio industry through the Korea Pavilion at Bio USA. This year, 13 domestic companies and institutions are planning to carry out various promotional activities together.
Participating companies in the Korea Pavilion include: ▲Kangstem Biotech, a stem cell treatment developer ▲BIO3S, which develops viral infectious disease response and diagnostic technologies ▲Standigm, an AI-based new drug developer ▲IMBDX, with liquid biopsy-based solution technology ▲Evidnet, a medical data platform company ▲DT&Sanomedics, a clinical trial contract organization (CRO) ▲RudaCure, a dry eye disease treatment developer ▲Aigen Science, an AI-based new drug developer ▲S&K Therapeutics, a new drug developer for autoimmune and inflammatory diseases ▲LSK Global Pharma Services, a CRO company ▲JD Bioscience, a new drug developer for metabolic disease treatments ▲Tego Science, a skin cell therapy developer — a total of 12 companies will participate in the Korea Pavilion to exhibit and introduce their respective biotechnologies and products. Chuncheon Bio Industry Promotion Institute will also participate to support promotion of Chuncheon-based companies.
아시아경제: 바이오협회, 2022 바이오 USA에서 한국관 운영
